**Core Concept**
Rosiglitazone is a thiazolidinedione (TZD) class of oral hypoglycemic agents that primarily work by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose tissue, skeletal muscle, and the liver. This activation enhances insulin sensitivity, reducing glucose levels without stimulating insulin secretion.

**Why the Correct Answer is Right**
Rosiglitazone does not cause hypoglycemia because it does not stimulate insulin secretion directly. Instead, it increases insulin sensitivity, reducing glucose levels by facilitating glucose uptake in peripheral tissues. This mechanism is distinct from sulfonylureas, meglitinides, and insulin secretagogues, which can cause hypoglycemia. Rosiglitazone's action on PPAR-γ also reduces hepatic glucose output, further contributing to its glucose-lowering effects without increasing the risk of hypoglycemia.

**Why Each Wrong Option is Incorrect**
**Option A:** Repaglinide is a meglitinide class oral hypoglycemic agent that works by closing potassium channels in the pancreatic beta-cell, stimulating insulin secretion. This action can lead to hypoglycemia, making it a less suitable option for minimizing hypoglycemic risk.
**Option B:** Gliclazide is a sulfonylurea class oral hypoglycemic agent that works by closing ATP-sensitive potassium channels in the pancreatic beta-cell, stimulating insulin secretion. This mechanism can also lead to hypoglycemia, making it less suitable for minimizing hypoglycemic risk.
**Option D:** Glimipiride is another sulfonylurea class oral hypoglycemic agent with a similar mechanism of action to gliclazide, leading to insulin secretion and an increased risk of hypoglycemia.

**Clinical Pearl / High-Yield Fact**
When choosing oral hypoglycemic agents for patients at risk of hypoglycemia, consider the mechanism of action and potential side effects. Thiazolidinediones like rosiglitazone are often preferred in patients with a high risk of hypoglycemia or those who require minimal glucose-lowering therapy.

**✓ Correct Answer: C. Rosiglitazone**